GLP-1s fail to slow progression of Alzheimer’s: Novo Nordisk

Novo Nordisk announced Monday that in two closely watched studies, an oral version of semaglutide — the active ingredient in ...

There’s still hope GLP-1 drugs could slow the second most common type of dementia

Novo Nordisk NVO announced Monday that its oral GLP-1 called Rybelsus wasn’t better than a placebo at delaying the progression of Alzheimer’s disease. It shared few details beyond saying the ...
C&EN

Nov. 25 Business Watch: Flexsys readies safer tire additive; Moderna halts trials of 3 mRNA drugs

C&EN networking event in New York City. Please join us if you’re in town! Here’s a link to the invitation. Questions? Comments? Tips? Let us know. Email Michael McCoy, C&EN’s executive editor for ...
BioPharma Dive

How do Big Pharma employees rate their CEOs?

Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.